Ruxolitinib FDA approval date

The FDA approved Ruxolitinib (JAKAFI) on 16 Nov 2011.

FDA approval date
16 Nov 2011

Drug identity checked against registry records

Also recorded as JAKAFI; Jakafi

Included trials

TrialSponsorPhaseStatusPrimary completion
Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisNCT04562389KPTIPhase 3Active not recruiting2026-02-20Actual
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaNCT05980806KPTIPhase 2Recruiting2027-06Estimated
Actuate 1901: 9-ING-41 in MyelofibrosisNCT04218071ACTUPhase 2Completed2022-10-13Actual

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2011-11-16DayRuxolitinibFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "NDA202192", "applicant_as_listed_by_fda": "INCYTE CORP", "brand_names": ["JAKAFI"], "active_ingredients": ["RUXOLITINIB PHOSPHATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20111116", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026